New pill shows promise for Tough-to-Treat lymphoma
NCT ID NCT06511895
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested an oral drug called AZD4205 in 57 adults with relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer. The study aimed to see if the drug can shrink tumors and how safe it is. Participants took a capsule once daily in 28-day cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD4205 (an oral drug taken as a capsule once daily)
What this could lead to
If successful, this could provide a new treatment option for people with peripheral T-cell lymphoma that has not responded to prior therapy.
What could go wrong
This is a small, early-phase trial (57 participants) with no comparison group. The drug may not work for many patients, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital (The First Affiliated Hospital of USTC)
Hefei, Anhui, China
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
-
Hainan General Hospital
Haikou, Hainan, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
-
Peking University Third Hospital
Beijing, Beijing Municipality, China
-
Ruijing Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
-
Shandong Cancer Hospital & Insititution
Jinan, Shandong, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Bethune Hospital of Jilin University
Changchun, Jilin, China
-
The Second Hospital of Anhui Meidcine University
Hefei, Anhui, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China